Grant of share options

RNS Number : 4488Z

Destiny Pharma PLC

25 January 2022

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of share options

Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following options ("Options") over a total of 54,282 ordinary shares of 1 pence in the Company have been granted under the Destiny Pharma plc 2020 Long Term Incentive Plan (the "Plan") to the following Directors and PDMR in respect of bonuses due for the financial year ended   31 December 2021:

Name	Position	Options issued Under 2020 LTIP scheme	Total Options held post issue	Percentage of options in the Company held	Ordinary Shares held	Ordinary Shares held as a percentage of issued share capital
Neil Clark	Chief Executive Officer	16,914	1,372,534	2.29%	38,462	0.06%
Shaun Claydon	Chief Financial Officer	11,725	863,901	1.44%	-	-
William Love*	Chief Scientific Officer	11,501	1,322,736	2.20%	6,509,500	10.87%
Stephanie Bewick	Chief Business Officer and PDMR	14,142	138,709	0.23%	-	-

*3,317,700 of these Ordinary Shares are held by William Love and 3,191,800 are held by Carole Love 

The Options have been granted with a nominal exercise price and will vest on 24 January 2024. The Options were granted under award agreements that incorporated the terms of the Plan.

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

[phone] 

[e-mail]  

Optimum Strategic Communications 

Mary Clark / Manel Mateus / Vici Rabbetts

[phone]

[e-mail]  

finnCap Ltd  (Nominated Adviser and Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners  (Joint Broker) 

Nigel Barnes / Claes Spång/Satheesh Nadarajah

[phone]  

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Neil Clark
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share  16,914 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	24 January 2022
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shaun Claydon
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 11,725 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	24 January 2022
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	William Love
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 11,501 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	24 January 2022
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stephanie Bewick
2.	Reason for the Notification
a)	Position/status	Chief Business Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 14,142, Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	24 January 2022
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END

 

 

DSHBIMPTMTBTBPT